Mass balance and metabolite profiling of 14 C-guadecitabine in patients with advanced cancer

Conclusion The metabolic and excretory pathways of guadecitabine and its metabolites were successfully characterized after subcutaneous guadecitabine administration in cancer patients. These data support the clinical evaluation of safety and efficacy of the subcutaneous guadecitabine drug product.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research